P. Wijermans

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Bruce D. Cheson, John M. Bennett, Hagop M. Kantarjian et al. · PubMed · 2000 · 665 citations

Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients

P. Wijermans, Michael Lübbert, G. Verhoef et al. · Journal of Clinical Oncology · 2000 · 570 citations

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Michael Lübbert, Björn Rüter, Rainer Claus et al. · Haematologica · 2011 · 230 citations · Full text

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

H M Lokhorst, Ingo GH Schmidt-Wolf, Pieter Sonneveld et al. · Haematologica · 2007 · 142 citations · Full text

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

Jan J. Cornelissen, Jurjen Versluis, Jakob Passweg et al. · Leukemia · 2014 · 129 citations · Full text

Hematological Malignancy, Post-remission Approaches, Medicine +9